Search SGMOQ
SANGAMO THERAPEUTICS, INC
OTC · CIK 1001233
Last close0.15
Daily change+0.00 (0.00%)
10 Years gain-96.75%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SGMOQ · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
8.6Momentum
0.0Acceleration
0.0Confidence
75.0Annual Revenue17
Quarterly Revenue71
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality8.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 120.4519 percentage points.
Heavy share dilution · HIGHDiluted share count increased 81.7875%.
Key Metrics
Revenue Growth TTM-55.13%OK
Revenue CAGR 3Y-29.17%OK
Gross Margin100%OK
Operating Margin-429.58%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y81.79%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $39.55M | $39.55M | -$121.24M | -$97.21M | -$97.31M | 100% | -306.53% | -246.03% | n/a | 280.19M |
| 2025 FY Dec 31, 2024 | $57.80M | $57.80M | -$103.97M | -$67.14M | -$67.41M | 100% | -179.88% | -116.62% | -886.27% | 201.7M |
| 2024 FY Dec 31, 2023 | $176.23M | $176.23M | -$274.01M | -$224.84M | -$246.00M | 100% | -155.48% | -139.59% | -787.01% | 174.44M |
| 2023 FY Dec 31, 2022 | $111.30M | $111.30M | -$201.28M | -$223.63M | -$243.80M | 100% | -180.85% | -219.05% | -1,972.73% | 154.35M |
| 2023 FY Dec 31, 2021 | $110.70M | $110.70M | -$183.34M | -$233.25M | -$256.53M | 100% | -165.61% | -231.73% | n/a | 144.57M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $26.77M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-035067, 0001628280-25-038860 |
| Revenue Growth TTM | -55.13% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-035067, 0001628280-25-038860 |
| Revenue CAGR 3Y | -29.17% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-022029 |
| Revenue CAGR 5Y | -19.66% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-022029 |
| Gross Profit CAGR 3Y | -29.17% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-022029 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-035067, 0001628280-25-038860 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-035067, 0001628280-25-038860 |
| Operating Margin | -429.58% | Operating Income / Revenue | OK | 0001628280-26-035067, 0001628280-25-038860 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-035067 |
| Current Ratio | 0.7x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.07 | Revenue / Diluted Shares | OK | 0001628280-26-035067, 0001628280-25-038860 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001628280-26-022029 |